HER2

Strata will refer individuals with HER-2 mutations identified through its screening trial for consideration as subjects in Puma's SUMMIT trial.

The analysis of HER2 and HER3 mutation carriers emphasizes how these studies can lead both to broadening and to narrowing of the patient populations for targeted drugs.

Gencurix aims to achieve US FDA 510(k) clearance for its GenesWell BCT breast cancer prognostic test next year.

At the AACR annual meeting, researchers presented results from the Phase II SUMMIT trial investigating the pan-HER-targeted therapy neratinib.

The new system emphasizes the importance of tumor biology as an important prognostic indicator for women who undergo neoadjuvant therapy, the researchers said.

Data showed that patients who had pathologic complete response in the neoadjuvant setting after treatment with a regimen containing Genetech's Perjeta experienced better progression-free and disease-free survival.

NEW YORK (GenomeWeb) – Roche this week announced plans to acquire Seragon Pharmaceuticals, aiming to bolster its own breast cancer pipeline and improve the standard of care for hormone receptor-positive breast cancer.

A new study using gene expression profiling to divide patients from an adjuvant trastuzumab (Herceptin) clinical trial into subgroups based on their response to the drug has shown that adjuvant treatment in addition to chemotherapy might be effective even in HER2-negative patient

The American Society for Clinical Oncology and the College of American Pathologists have jointly issued updated guidelines in which they continued to recommend that oncolo

The US Food and Drug Administration has accepted a supplemental biologics license application for Perjeta (pertuzumab) as a neoadjuvant treatment for women with HER2-positive, early-stage breast cancer, Roche subsidiary Genentech announced this week.

Pages

York University researchers find genomic evidence of inbreeding in the yellow-banded bumblebee, according to Reuters.

In its survey of US adults, the Pew Research Center finds that views on the genetic engineering of animals depend on why it's done.

The Scientist reports agricultural researchers are working on a gene-stacking tool.

In Nature this week: statistical method for overcoming case-control imbalance issues, and more.